Background: The efficacy of omalizumab on patient-reported outcomes (PROs) in severe allergic asthma has been reported in several randomized controlled trials. This systematic literature review aimed to summarize the effectiveness of omalizumab on PROs in real-world settings

Methods: The literature search was performed using PubMed, EMBASE, and Cochrane databases. It included studies using Global Evaluation of Treatment Effectiveness (GETE), Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT), and Asthma Control Questionnaire (ACQ) comparing 16 weeks, 6 months, 12 months, and end of the study post-treatment outcomes with baseline observations in patients with severe allergic asthma

Results: In total, 85 studies were included in this systematic review. GETE scores were consistently good or excellent in 53%–100% of patients receiving omalizumab across time points compared with baseline. Omalizumab treatment also improved health-related quality of life (HRQoL) and asthma control scores at all time points (Table). At the end of the studies, the proportion of participants who achieved minimal clinically important differences (MCID) for ACT (≥3), ACQ (≥0.5), and AQLQ (≥0.5) ranges from 50%–62%, 60%–95% and 72%–100%, respectively